PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
5.65
Current Ratio 1.25–1.5x Biotechnology median of 4.27. Mohnish Pabrai might suspect the market overlooks this liquidity advantage.
5.65
Quick Ratio 1.25–1.5x Biotechnology median of 4.15. Mohnish Pabrai might see the market underpricing this strong liquidity position.
5.13
Cash Ratio above 1.5x Biotechnology median of 2.21. Joel Greenblatt might see a strategic advantage in crisis periods.
-10661.81
Negative interest coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
No Data
No Data available this quarter, please select a different quarter.